Minnesota is currently home to 2089 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Recruiting
The main purpose of this study is to: * Learn about the safety of REGN4018 and to find out what dose of REGN4018 can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus * The study will also look at the levels of REGN4018 and/or cemiplimab in your body and measure how well your body can remove the study drug(s). This is called pharmacokinetics * The study will also look at any signs that REGN4018 alone or with cemiplimab can treat recurrent advanced ovarian... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: Mayo Clinic - Rochester, Rochester, Minnesota
Conditions: Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Recruiting
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
Gender:
ALL
Ages:
All
Trial Updated:
04/15/2025
Locations: Mayo Clinic Rochester, Rochester, Minnesota
Conditions: Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Severe Aplastic Anemia, Autoimmune Diseases
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Recruiting
This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Mesothelioma, Non Small Cell Lung Cancer, Malignant Peripheral Nerve Sheath Tumors, Solid Tumor, Pancreatic Adenocarcinoma, Advanced Solid Tumor
How Many Dexamethasone Doses Should Be Given Perioperatively?
Recruiting
The purpose of this study is to determine the most efficient and safest dexamethasone dose given perioperatively during total knee arthroplasty that reduces postoperative option consumption and pain, improves postoperative nausea and vomiting, and minimizes postoperative complications
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Arthropathy of Knee
PREVENT ALL ALS Study
Recruiting
The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium is begin funded by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) and managed by two clinical coordinating centers (CCC) at Barrow Neurological Institute and Massachusetts General Hospital. The cl... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Amyotrophic Lateral Sclerosis
Effect of Glucagon on Fasting Insulin Secretion and Glucose Metabolism in Subjects Without Type 2 Diabetes
Recruiting
Fasting hyperglycemia contributes disproportionately to nonenzymatic glycosylation and the microvascular complications of type 2 diabetes. However, little is known about the regulation of glucose concentrations in the fasting state relative to what is known about the postprandial state. The proposed experiment is part of a series of experiments designed to establish how glucagon and insulin interact with their receptors to control fasting glucose in health and in prediabetes.
Gender:
ALL
Ages:
Between 25 years and 65 years
Trial Updated:
04/14/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: PreDiabetes
A Study to Assess Growth in Children With Idiopathic Short Stature
Recruiting
Study 111-903 will generate baseline growth data in children with ISS by collecting growth measurements and other variables of interest.
Gender:
ALL
Ages:
Between 2 years and 16 years
Trial Updated:
04/14/2025
Locations: University of Minnesota Medical School - Masonic Children's Hospital - Pediatric Specialty Care Explorer Clinic, Minneapolis, Minnesota
Conditions: Idiopathic Short Stature
Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
Recruiting
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine the safety and pharmacokinetics of ABBV-383 in adult participants with relapsed/refractory (R/R) MM. ABBV-383 is an i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Mayo Clinic - Rochester /ID# 262807, Rochester, Minnesota
Conditions: Multiple Myeloma
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
Recruiting
REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in participants with a history of paroxysmal or persistent Atrial Fibrillation (AF) and low-to-moderate stroke risk.
Gender:
ALL
Ages:
Between 22 years and 85 years
Trial Updated:
04/14/2025
Locations: Essentia Health The Duluth Clinic, Duluth, Minnesota
Conditions: Atrial Fibrillation
Real-Time Cholangioscopy Artificial Intelligence Evaluation of Biliary Strictures
Recruiting
The purpose of this study is to demonstrate the feasibility and validity of a previously developed peroral cholangioscopy (POC) convolutional neural network (CNN) to determine the etiology of biliary strictures when used in real-time.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Mayo Clinic Minnesota, Rochester, Minnesota
Conditions: Biliary Stricture
The Cardiovascular Impact of Hot Flushes
Recruiting
The overall objective of this study is to examine the physiological responses that occur during a hot flush in postmenopausal women. The following specific aims will be executed to reach the overall objective of this study. Aim 1: To determine if hot flushes can be reliably induced with a temperature-controlled, water- circulating (TCWC) heating pad. Based on previous research, the investigators hypothesize that hot flushes will be inducible with the TCWC in symptomatic women, but not in asympto... Read More
Gender:
FEMALE
Ages:
Between 40 years and 70 years
Trial Updated:
04/14/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Hot Flashes, Menopause
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection
Recruiting
This is a first-in-human Phase 1/2, non-randomized, multi-centre, open-label clinical study designed to investigate safety, tolerability, PK, and preliminary anti-tumour activity of \[225Ac\]-FPI-1434 (radioimmuno-therapeutic agent) in patients with solid tumours that demonstrate uptake of \[111In\]-FPI-1547 (radioimmuno-imaging agent), and to establish the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of repeat doses of \[225Ac\]-FPI-1434 Injection in patients with sol... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Advanced Solid Tumours, Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Adrenocortical Carcinoma, Uveal Melanoma